Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancerAdding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from a Phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Novel endocrine therapy reduces the risk of breast cancer recurrenceNovel endocrine therapy reduces the risk of breast cancer recurrence
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.
Sperm donor with cancer-causing gene fathers nearly 200 children across EuropeSperm donor with cancer-causing gene fathers nearly 200 children across Europe
A genetic mutation that carries a 90% cancer risk has been passed on by an unwitting sperm donor to dozens of children, a Europe-wide investigation has revealed.
New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggestsNew Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. A study led by researchers at Karolinska Institutet and Stockholm University Read More
Celebrities With Breast Cancer: 22 Celebrities Whose Lives Have Been Touched by Breast CancerCelebrities With Breast Cancer: 22 Celebrities Whose Lives Have Been Touched by Breast Cancer
Among them: Celebs who are fighting for their lives, have faced a high-risk diagnosis, or have fought alongside someone they love dearly.
Enhancing breast cancer screening could help save young women’s livesEnhancing breast cancer screening could help save young women’s lives
In Estonia, breast cancer screening is offered from the age of 50, yet one-fifth of first diagnoses occur in younger women. A new clinical study has therefore been conducted to test better ways to detect the disease early.
The VA is making it harder for male veterans with breast cancer to get careThe VA is making it harder for male veterans with breast cancer to get care
Male breast cancer is rare, but studies suggest it’s more common — and more lethal — among veterans. Yet the Veterans Administration is making it harder for veterans with breast cancer to get care.
Breakthrough GLP-1 implant promises major weight-loss benefits for petsBreakthrough GLP-1 implant promises major weight-loss benefits for pets
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1 study of OKV-119 – an investigational “ultra-long acting” GLP-1 implant, which, according to a press release, is being developed for weight management in cats. OKAVA Pharmaceuticals, the San Francisco-based manufacturer Read More
After NIH grant cuts, breast cancer research at Harvard slowed, and lab workers leftAfter NIH grant cuts, breast cancer research at Harvard slowed, and lab workers left
Amid NIH funding delays, reversals and uncertainty, a scientist at Harvard who studies breast cancer has lost one-third of her lab employees and wonders if she can continue her research experiments.
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 DiabetesFDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions. The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, Read More